upadacitinib,linaclotide,risankizumab
Abbvie,ironwood pharmaceutical,Boehringer Ingelheim
['abbvie']
abbvie releases new data demonstrating breadth of its gastroenterology portfolio at 2023 digestive disease week 
Finance enthusiast and renaissance man with a passion for learning, exploring, and creating. Enjoy posting news and musings. Proceed at your own caution.